Introduction Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder, that typically manifests in adulthood, clinically characterized by progressive motor, cognitive and psychiatric/behavioural symptoms. Psychiatric symptoms are common in HD. The presentation of these symptoms is highly variable, and their course does not correlate with motor or cognitive disease progression. Psychiatric symptoms often precede motor onset by many years.ObjectivesThe authors intend to review the literature the most frequent psychiatric disorders in patients with HD.MethodsNon-systematic review of the literature.ResultsPsychiatric symptoms have been a core feature of HD. Pre-symptomatic HD patients exhibit a greater prevalence of psychiatric symptoms, particularly affective disorders. This symptoms are presenting symptoms of HD in up to half of all people. In symptomatic HD patients, it is estimated that up to 73–98% of patients will have a major psychiatric disorder or psychiatric symptoms. Psychiatric manifestations in HD include depression, irritability, apathy, anxiety, mania, perseverations, obsessions and psychosis. Cognitive changes include progressive deficits in attention, learning, executive and sensory functions, resulting in dementia. Depression, diagnosed in half of patients with HD, is the most common and earliest symptoms prior to the motor onset. There are likely multiple causes of the psychiatric symptoms, with underlying factors including a combination of neurobiological, cognitive, psychological, social and environmental factors.ConclusionsPatients with HD have high psychiatric comorbidity, that causes significant functional impairment and affect quality of life. Thus, they require a multidisciplinary approach in the recognition and treatment of psychiatric symptoms.

The prevalence of people in mental distress has increased in recent decades and has influenced the quality of life of the population. This work seeks to investigate the trend to depression based on symptoms in subelite athletes and athletes, enabling to illustrate the mental health situation of these populations. The study included 50 athletes and 30 sports athletes, 7 were female and 43 were male athletes, and 8 were women and 22 were men among the sports athletes. The instruments were used for the characterization of the sample containing items to do the profile and the Beck Depression Inventory II (BDI-II). The Mann-Whitney U test for the Beck Depression Inventory among athletes and sub-elite athletes showed the lowest prevalence of symptoms among them (U=495.5, p=.011). When comparing by gender [F(1.75)=1.144, p=.288] and by age [F(2.75)=.160, p=.852], there was no statistical difference between groups. The difference was perceived regarding the trend according to the cutoff points of BDI-II. For gender and age, all athletes, except for males, showed a slight trend and in all cases, athletes were classified with minimal trend. Athletes have a minimal trend, being less vulnerable to depression than sports athletes. depression Collective sports athletes were less vulnerable than individual athletes and sportsmen, and the athlete status was associated and correlated with the trend toward symptom-based.

IntroductionDelusional infestation (DI), also known as delusional parasitosis or Ekbom syndrome, is a rare disorder, characterised by fixed belief that the skin, body or immediate environment is infested by small pathogens, despite the lack of any medical evidence for it.ObjectivesTo describe and discuss two clinical cases of DI, in order to show two different ways of presenting in this entity.MethodsTwo case report and non-systematic review.ResultsWe present the case of a 76-year-old woman, without psychiatric history, with an DI with 5 years of evolution, referred to a psychiatric consultation by a dermatologist. The second case, is a 41-year-old woman with a history of multiple substance use disorder, with an DI with a month of evolution, who resorted to the emergency department. DI is not a single diagnostic entity. The classic form, as represented in the first case,is a primary form, which develops without any known cause or underlying disease, corresponding to a persistent delusional disorder. However, about 60% of patients have secondary forms of DI, in the context of substance misuse, some medications or in the course of physical or psychiatric diseases (e.g. stroke, delirium, dementia, depression, schizophrenia).ConclusionsDI can occur as a primary delusional disorder or secondary to several other medical conditions. An in-depth clinical history is essential in order to make the correct diagnosis. A multidisciplinary approach is also important, to exclude any possible organic etiology, not forgetting that many patients may turn to other medical specialities first.DisclosureNo significant relationships.

IntroductionRecently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the treatment of multiple psychiatric illnesses.ObjectivesThe authors intend to review the literature on the clinical application of psychedelic drugs in psychiatric disorders.MethodsNon-systematic review of the literature.ResultsIn recent clinical trial the psychedelic is given with psychotherapeutic input. In a supportive setting, psychedelics produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months. Randomized clinical trials support the efficace of psilocybin in the treatment of depression and those with anxiety and depression symptoms provoked by life-threatening cancer. There have also been studies showing efficacy in both alcohol and tobacco dependence. When administered safely LSD can reduce anxiety and have anti-addictive property. Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD. Psychedelics were well-tolerated, few adverse effects have been reported. The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure, with no persisting adverse effects. Serious adverse events, such as persistent psychosis and suicidality, have not been demonstrated.ConclusionsPsychedelics appear to be effective in multiple psychiatric disorders and are well-tolerated, although further evidence is required, to better see they therapeutic potential.DisclosureNo significant relationships.